|
Adverse End Point
|
Exposure Data
|
Species and Reference
|
LOAEL/NOAEL
|
Acceptable Concentrations, ppm
|
|
1h
|
24 h
|
7 d
|
30 d
|
180 d
|
1,000 d
|
|
Ocular and throat irritation and slight dyspnea
|
Inhalation of PG; 1 min; mean concentration = 309 mg/m3 (~ 96 ppm)
|
Human, Wieslander et al. 2001
|
LOAEL = 96 pp
|
32
|
—
|
—
|
—
|
—
|
—
|
|
Nasal hemorrhage and ocular discharge
|
Inhalation of PG; 6 h/d, 5 d/wk; 0.16, 1.01, 2.18 mg/L (160, 1,000, 2,200 mg/m3 or 50, 313, 688 ppm)
|
Sprague-Dawley rat, Suber et al. 1989
|
NOAEL for 1 wk = 50 ppm; ten Berge method used
|
—
|
17
|
—
|
—
|
—
|
—
|
|
Nasal hemorrhage and ocular discharge
|
Inhalation of PG; 6 h/d, 5 d/wk; 0.16, 1.01, 2.18 mg/L (160, 1,000, 2,200 mg/m3 or 50, 313, 688 ppm)
|
Sprague-Dawley rat, Suber et al. 1989
|
NOAEL for 1 wk = 50 ppm
|
—
|
—
|
9
|
—
|
—
|
—
|
|
Nasal hemorrhage and ocular discharge
|
Inhalation of PG; 6 h/d, 5 d/wk; 0.16, 1.01, 2.18 mg/L (160, 1,000, 2,200 mg/m3 or 50, 313, 688 ppm)
|
Sprague-Dawley rat, Suber et al. 1989
|
LOAEL for 2 wk = 50 ppm
|
—
|
—
|
—
|
3
|
—
|
—
|
|
Thickening of respiratory epithelium with increased goblet cells and their mucin
|
Inhalation of PG; 6 h/d, 5 d/wk; 0.16, 1.01, 2.18 mg/L (160, 1,000, 2,200 mg/m3 or 50, 313, 688 ppm)
|
Sprague-Dawley rat, Suber et al. 1989
|
NOAEL = 50 ppm
|
—
|
—
|
—
|
—
|
1.5
|
1.5
|
|
SMACs
|
|
|
|
32
|
17
|
9
|
3
|
1.5
|
1.5
|
|
Abbreviations: LOAEL, lowest-observed-adverse-effect level; NOAEL, no-observed-adverse-effect level; —, not calculated.
|